Who makes Monocyte derived DCs loaded with KRN7000?

Monocyte derived DCs loaded with KRN7000 is developed by Yale University.

What development phase is Monocyte derived DCs loaded with KRN7000 in?

Monocyte derived DCs loaded with KRN7000 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Monocyte derived DCs loaded with KRN7000

Yale University · Phase 1 active Biologic Quality 0/100

Monocyte-derived dendritic cells (DCs) pulsed with KRN7000 are an investigational immunotherapy being studied for the treatment of myeloma. The therapy aims to enhance the immune response against cancer cells by activating T-cells. Early clinical trials have shown promise, but further research is needed.

At a glance

Generic name	Monocyte derived DCs loaded with KRN7000
Also known as	α-galactosyl-ceramide, α-GalCer
Sponsor	Yale University
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Monocyte derived DCs loaded with KRN7000 CI brief — competitive landscape report
Monocyte derived DCs loaded with KRN7000 updates RSS · CI watch RSS
Yale University portfolio CI